Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
Arrange urgent assessment for rapidly spreading pain, fever, extensive blistering, erythroderma, severe lower-leg infection or a non-healing ulcerated plaque suspicious for malignancy.
Synopsis
Distinguish coin-shaped discoid eczema from fissured asteatotic eczema, exclude dermatophyte infection and venous disease, and treat dryness and inflammation without masking important mimics.
Discoid eczema forms very itchy round or oval plaques, often weepy and crusted early and dry or scaly later; it commonly mimics tinea corporis.
Asteatotic eczema produces superficial intersecting cracks on very dry skin, often shins of older adults in cold dry conditions.
On brown or black skin, active discoid plaques may appear dark brown, purple or paler and often leave persistent pigment change.
A solitary enlarging indurated plaque with bleeding, ulceration or failure of adequate therapy requires prompt specialist assessment.
Investigation priorities
01
Whole-skin, foot and nail examinationFirst step
Distinguish discoid and asteatotic patterns from psoriasis, venous disease and a fungal reservoir.
Management branches
Dry or asteatotic diseaseRestore barrier and reduce environmental loss
Craquelé fissures occur on dry skin without infection, tumour features or major venous disease.
Shorten hot washing, stop harsh soap and apply a rich fragrance-free leave-on emollient at least twice daily and after washing.
Use a site-appropriate topical corticosteroid on inflamed fissured areas for a defined short course while continuing emollient beyond clearance.
Key medicines
Betamethasone valerate 0.1% creamApply a thin film to active trunk or limb plaques once or twice daily for up to four weeks, reducing frequency when inflammation is controlled.
Hydrocortisone 1% creamAdults apply thinly once or twice daily for no more than seven days under the product licence on appropriately selected mild or thin-site inflammation.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.